Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies

Clinical Infectious Diseases

Volumn 31, Issue 1, 2000, Pages 58-64

  Scheifele, David ^a,n   Halperin, Scott ^a,d   Pelletier, Louise ^b   Talbot, James ^c   Morris, Robert ^e   Déry, Pierre ^f   Lebel, Marc ^g   Mills, Elaine ^h   MacDonald, Noni ⁱ   Gold, Ron ^j   Wang, Elaine ^j   Law, Barbara ^k   Jadavji, Taj ^l   Vaudry, Wendy ^m   Marchessault, Victor ^o   Delage, Gilles ^o   Duclos, Phillipe ^b   Pless, Robert ^b   Kertesz, Daniel ^b   Waters, John ^p  

^a HEALTH CANADA   (Canada)

^b LAB CENTRE FOR DISEASE CONTROL   (Canada)

^c National Centre for Streptococcus   (Canada)

^d IWK HEALTH CENTRE   (Canada)

^e New Janeway Childrens Health and Rehabilitation Centre   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITY OF MONTREAL   (Canada)

^h MONTREAL CHILDREN S HOSPITAL   (Canada)

ⁱ CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

^l ALBERTA CHILDREN'S HOSPITAL   (Canada)

^m Health Sciences Centre   (Canada)

ⁿ BC CHILDREN S HOSPITAL   (Canada)

^o CPS   (Canada)

^p Alberta Health   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G; PNEUMOCOCCUS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BACTERIUM ISOLATE; CANADA; CHILD; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PEDIATRIC HOSPITAL; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS INFECTION; VACCINATION;

BACTEREMIA; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENINGITIS, PNEUMOCOCCAL; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0034457663     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313923     Document Type: Article

References (42)

1. Infections caused by Streptococcus pneumoniae clinical spectrum, pathogenesis, immunity, and treatment
2. Pneumococcal bacteremia in infants and children: A 10-year experience at the Cook County Hospital with special reference to the pneumococcal serotypes isolated
3. Three-year multicenter surveillance of systemic pneumococcal infections in children
4. Infection caused by Streptococcus pneumoniae in child ten with sickle cell disease: Epidemiology, immunologic mechanisms, prophylaxis, and vaccination
5. Penicillin resistance among invasive pneumococcal isolates at 10 children's hospitals, 1991-1994
6. Drug-resistant Streptococcus pneumoniae
7. The continued emergence of drug-resistant Streptococcus pneumoniae in the US: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System
8. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae
9. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results of the SENTRY Antimicrobial Surveillance Program
10. Invasive Streptococcus pneumoniae infections: Serotype distribution and antimicrobial resistance in Canada, 1992-1995
11. Antibody response to pneumococcal vaccination in children younger than 5 years of age
12. Prevention of pneumococcal disease
13. Pneumococcal conjugate vaccines
14. Pneumococcal disease: Prospects for a new generation of vaccines
15. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: Impact on pneumonia, otitis media and an update on invasive disease-Results of the Northern California Kaiser Permanente efficacy trial
16. Six newly recognized types of Streptococcus pneumoniae
17. IMPACT monitoring network: A better mousetrap
18. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: Ethnic differences and opportunities for prevention
19. The Israeli Pediatric Bacteremia Meningitis Group. Epidemiology of invasive childhood pneumococcal infections in Israel
20. Invasive Streptococcus pneumoniae infection in Latin American children: Results of the Pan American Health Organization Surveillance Study
21. Epidemiology of invasive pneumococcal infections in children in Finland
22. Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut
23. 197 in US infants
24. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
25. Pentavalent pneumococcal oligosaccharide conjugate vaccine Pnc CRM is well-tolerated and able to induce an antibody response in infants
26. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
27. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
28. Immunogenicity and impact on nasopharyngeal carriage of a nonvalent pneumococcal conjugate vaccine
29. For the Active Bacterial Core Surveillance Team. Risk factors for invasive pneumococcal disease in children: A population-based case-control study in North America
30. The Toronto Invasive Bacterial Diseases Network Assessing the potential impact of vaccination programs on invasive pneumococcal disease: Data from population-based surveillance
31. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease
32. Serogroup-specific epidemiology of Streptococcus pneumoniae: Associations with age, sex, and geography in 7000 episodes of invasive disease
33. Serotype distribution of Streptococcus pneumoniae infections among pre-school children in the US, 1978-1994: Implications for development of a conjugate vaccine
34. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations
35. Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974
36. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants
37. Considerations for formulating the 2d-generation pneumococcal capsular polysaccharide vaccine, with emphasis on the cross-reactive types within groups
38. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children: Implications for vaccine strategies